Signaturefd LLC Has $115,000 Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Signaturefd LLC cut its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 40.8% during the 4th quarter, HoldingsChannel reports. The firm owned 7,746 shares of the company’s stock after selling 5,345 shares during the period. Signaturefd LLC’s holdings in Elanco Animal Health were worth $115,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ELAN. Primecap Management Co. CA grew its stake in shares of Elanco Animal Health by 0.4% during the third quarter. Primecap Management Co. CA now owns 49,168,659 shares of the company’s stock worth $552,656,000 after buying an additional 172,205 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Elanco Animal Health by 0.7% during the third quarter. Vanguard Group Inc. now owns 49,001,441 shares of the company’s stock worth $550,776,000 after purchasing an additional 362,152 shares during the last quarter. Black Creek Investment Management Inc. increased its stake in shares of Elanco Animal Health by 12.8% in the third quarter. Black Creek Investment Management Inc. now owns 15,523,457 shares of the company’s stock valued at $174,484,000 after buying an additional 1,759,556 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Elanco Animal Health by 7.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 5,003,011 shares of the company’s stock valued at $56,234,000 after buying an additional 354,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Elanco Animal Health by 20.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,711,180 shares of the company’s stock worth $52,954,000 after buying an additional 814,668 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 2.3 %

Shares of Elanco Animal Health stock opened at $13.57 on Tuesday. The firm has a market cap of $6.70 billion, a price-to-earnings ratio of -5.43, a PEG ratio of 1.39 and a beta of 1.29. The stock’s 50-day moving average is $15.31 and its 200 day moving average is $13.85. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35. Elanco Animal Health Incorporated has a one year low of $7.88 and a one year high of $16.88.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. Elanco Animal Health’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.19 earnings per share. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insiders Place Their Bets

In related news, Director R David Hoover acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the acquisition, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ELAN. The Goldman Sachs Group raised their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a research note on Tuesday, February 27th. Barclays raised their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Stifel Nicolaus raised Elanco Animal Health from a “hold” rating to a “buy” rating and increased their price target for the company from $13.00 to $20.00 in a research note on Friday, January 5th. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a research note on Friday, February 23rd. Finally, Morgan Stanley upped their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $16.71.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.